The intrinsic and acquired resistance to EGFR-TKIs might occur through numerous mechanisms, including EGFR T790M mutation, PI3K mutations, HER-2 amplification, MET amplification, and alteration into an SCLC phenotype resulting in the poor clinical outcomes of these agents [10,77,174]. This evidence concerns the gene EGFR and small cell lung carcinoma.